Title :

An update on the management of sporadic desmoid-type fibromatosis: a european consensus initiative between sarcoma patients euronet (spaen) and european organization for research and treatment of cancer (eortc)/soft tissue and bone sarcoma group (stbsg)

Author(s) :

Kasper, Bernd [Auteur]
University of Heidelberg, Medical Faculty
Baumgarten, C. [Auteur]
Garcia, J. [Auteur]
Bonvalot, Sylvie [Auteur]
Institut Curie [Paris]
Haas, R. [Auteur]
Antoni van Leeuwenhoek Hospital
Haller, F. [Auteur]
Friedrich-Alexander Universität Erlangen-Nürnberg = University of Erlangen-Nuremberg [FAU]
Hohenberger, P. [Auteur]
University of Heidelberg, Medical Faculty
Penel, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Messiou, C. [Auteur]
Van Der Graaf, W. T. [Auteur]
The institute of cancer research [London]
Gronchi, A. [Auteur]
Molecular Targeting Unit, Department of Research [Fondazione IRCCS Istituto Nazionale dei Tumori, Milan]

Journal title :

Annals of oncology . official journal of the European Society for Medical Oncology

Abbreviated title :

Ann. Oncol.

Volume number :

28

Pages :

2399-2408

Publication date :

2017-10-01

ISSN :

0923-7534

English keyword(s) :

aggressive fibromatosis
EORTC/STBSG
patient advocacy groups
SPAEN
treatment algorithm
desmoid
Mesh:Humans
Mesh:Fibromatosis
Mesh:Aggressive/therapy*
Mesh:Fibromatosis
Mesh:Aggressive/genetics
Mesh:Fibromatosis
Mesh:Aggressive/diagnosis*
Mesh:Randomized Controlled Trials as Topic

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based ...
Show more >Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T18:16:56Z
2020-05-28T09:28:01Z